Gerry Sullivan

Bristol Myers Is the Icing on Mead Johnson Nutrition's IPO

I am the author of the article above. I am participating in the Mead Johnson Nutrition IPO (MJN) not because I think it is a great deal but because it seems to have demand from institutional investors and might pop.
.
Jim Cramer said that Wall Street wants this deal to work.
So, I am also long MJN now on the offering priced at $24.

I didn't have any difficulty getting shares from 3 different firms. Maybe it
isn't that tight a deal.

I still consider that BMY and JNJ are better investments.